WHITEFISH, MT / ACCESSWIRE / November 19, 2014 / A growing body of data from numerous studies over the past decade has gradually led to a more complete understanding of cannabinoid biology and pharmacology, including efficacy as an appetite stimulant, analgesic (pain reliever) and treatment for neurological disorders like epilepsy. Similar efficacy data regarding cannabinoids performing broad-spectrum anti-tumor functions and producing palliative effects on cancer symptoms, documented by the National Cancer Institute, has made cannabinoid science a hot property in the world of modern oncology medicine. Needless to say, the emerging market surrounding cannabinoids has been booming of late, with a variety of sector players seeing increased interest from investors, ranging from cannabis-based medicine developers like Cannabis Science (CBIS), to innovative medical cannabis-focused healthcare solution providers, like Novus Acquisition & Development (NDEV).
Tetrahydrocannabinol (THC), the psychoactive phytocannabinoid (planet-based) found in cannabis, has rapidly become eclipsed by the non-psychoactive phytocannabinoid, cannabidiol (CBD), which is considered to have wider-ranging medical applications. CBD has even received orphan drug status in the U.S., fast-tracking the substance for use in treating a severe, rare form of crippling epilepsy known as Dravet Syndrome, popularized by the now-famous case of Charlotte Figi, a seven year old girl whose condition has been greatly aided by use of a CBD-rich strain of medical marijuana known as Charlotte's Web. Epidiolex(R), a highly purified CBD extract developed by UK-based GW Pharmaceuticals (GWPH), has now gone into landmark clinical trialing for epilepsy at the biggest children's hospital herein the states, Texas Children's Hospital, with initial trials that began in April of 2014 already having shown encouraging results in kids with treatment-resistant epilepsy. More comprehensive objective measurements and standardized preparation testing are in increasingly high demand across the board for CBD these days, due to a compelling combination of study data, mounting empirical evidence, and positive feedback from parents whose children suffer from debilitating seizures.
Promising Results & A Steady CBD Supply, Legal In All 50 States
Earth Science Tech (ETST) has been working hard to get out ahead of the yet-nascent CBD market and looks to establish itself as a front-runner in the space by building a strong IP portfolio. The company has already acquired a ready supply of food-grade, Hemp Oil Enriched with CBD, a product which nimbly leaps over lagging regulatory hurdles, as the product is currently legal in all 50 states and over 40 countries worldwide. Positive preliminary results obtained in October via the company's ongoing Sponsored Research Agreement with the University of Central Oklahoma (UCO), showing an approximately 90% inhibition rate with the appropriate dosing in breast cancer cells (only 50% inhibition for normal cells demonstrates efficacy nicely), using their Hemp Oil Enriched with CBD in animal models, subsequently led to a provisional patent filing with the USPTO (United States Patent and Trademark Office). Invasive breast cancer currently hits about one in every eight U.S. women, with around 40k fatalities estimated for 2014 alone, despite gradually improving death rates due to medical advancements.
CannabisFN Executive Interview | Earth Science Tech. (ETST) / Harvey Katz - CEO from TDM Financial on Vimeo.
The patent filing by CEO of Earth Science Tech, Dr. Harvey Katz and esteemed UCO Biomedical Engineering Program professor, and lead investigator for the Sponsored Research Agreement, Dr. Wei Chen, a veteran laser cancer treatment specialist who received his master's and Ph.D. degrees in theoretical high-energy physics from the University of Oregon, brings with it the promise of a whole host of new claims over the next year, leading up to the eventual utility patent filing. The provisional patent filing (#62061577 "Cannabidols Composition and Uses Thereof") covers the company's proprietary Hemp Oil Enriched with CBD and Hemp Oil Enriched with Proprietary Additives, and has already been assigned by both parties to Earth Science Tech.
Evolving IP Portfolio/Product Mix, Ongoing Efficacy Validation
The ongoing CBD work at UCO is now in Stage 2, with further study of the product's effectiveness in inhibiting cancer cell proliferation and its effect on immune cells in particular, at the top of the schedule. Earth Science Tech is firmly dedicated to not only formulating a diverse array of all natural solutions for oncology, but fully vetting the emerging product lines with rigorous research and testing. The company is looking to create multiple patents and execute validating clinical trials to back up their proprietary CBD formulations, tapping fully into both the prevailing market dynamics and ETST's shrewdly engineered capacity to supply a steady stream of high-grade CBD to all 50 states.
The ability of Earth Science Tech's CBD product to be sold legally across the U.S. is particularly telling in light of the unexpected rejection in Florida of Amendment 2 earlier this month, which failed to acquire the necessary 60% majority required by state law and would've made medical marijuana (MMJ) legal throughout the state. Despite Amendment 2's strong lead-in support, with polls showing nearly 90% of the public supported the measure, and clear language in the amendment detailing how doctors would be able to prescribe MMJ for a variety of debilitating conditions, including ALS, cancer, MS, and Parkinson's disease, the only current hope for Floridians suffering from these afflictions now falls to innovators like ETST.
Lead Investigator's Laser Breast Cancer Treatment/Diagnostics Expertise Key
Dr. Chen, who is also UCO's Assistant Dean of the College of Mathematics & Science, is a world-renown scientist and researcher, possessing a considerable decade-plus track record in laser breast cancer treatment research and is also a fellow at the leading not-for-profit interdisciplinary organization dedicated to advancing the science and application of light, the International Society for Optics and Photonics. The driving force behind the formation and success of UCO's biomedical engineering program, Dr. Chen has published over 50 research articles to date and pulled down over $1.2M in research grants from both public and private sources.
Dr. Chen's in-depth knowledge of the underlying physics of laser breast cancer treatments has been and will continue to be instrumental when it comes to advancing ETST's work in CBD, and his laboratory at UCO will act as a proving ground for the company's eventual manufacturing and marketing of a whole range of products based on Hemp Oil Enriched with CBD, including nutraceutical and palliative offerings. Dr. Chen has established an impressive body of work in laser-tissue interactions (both soft and hard tissues), including laser-induced anti-tumor immunology responses and laser photothermal cancer treatments (employing laser absorbing dye and an immunoadjuvant), and he is one of the top pioneers today in the field of simulating light transport in tissues, as well as doing cutting-edge imaging techniques for monitoring the efficacy of cancer treatments.
Earth Science Tech is gunning to be one of the top players in the broader nutraceutical and dietary supplement space, which is estimated by Research and Markets as growing to over $75.9B in the U.S. alone in the next four years, with an array of health and wellness formulations based on their CBD research. ArcView estimates the retail MMJ space at around $2.34B this year, meaning there is plenty of room to grow for CBD-focused companies like Earth Science Tech and related CBD/nutraceutical developers such as CannaVEST Corp. (OTC:CANV).
For Additional Information Please Visit:
- Company Website - http://www.earthsciencetech.com/
- OTC Markets Profile - http://www.otcmarkets.com/stock/ETST/quote
Click Here to Sign Up For Future Email Updates on Earth Science Tech.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/
SOURCE: Emerging Growth LLC